Skip to main content
MedPathMedPath Home
Clinical Trials/CTRI/2023/10/059282
CTRI/2023/10/059282
Completed
未知

A double-blind, randomized, single centre, two-arm, placebo-controlled, comparative clinical study to evaluate the safety, in-use tolerability and efficacy of Moisturizing Cream in female subjects with varied skin type. - NI

DPKA Universal Consumer Ventures Private Limited0 sites96 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
DPKA Universal Consumer Ventures Private Limited
Enrollment
96
Status
Completed
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
January 1, 2024
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
DPKA Universal Consumer Ventures Private Limited

Eligibility Criteria

Inclusion Criteria

  • •1\) Subjects with dry / normal / oily / sensitive skin.
  • •oSubjects with self\-perceived normal skin.
  • •oSubjects with dry (readings between 30 – 40\) as assessed by MoistureMeterSC.
  • •oSubjects with oily skin having Sebumeter measurement \> 150 (µg/cm2\).
  • •oSubjects with sensitive skin based on Dr. Baumann’s skin type questionnaire.
  • •2\) Subjects having good general health as determined by the Investigator on the basis of medical history.
  • •3\) Females of Childbearing potential must have a negative urine pregnancy test performed during Visit 01\.

Exclusion Criteria

  • •1\) Subjects undergoing treatment for skin lightening or subjects using other marketed skin lightening products during the study period or in the past 6 weeks.
  • •2\) Subjects who are receiving topical or systemic treatments.
  • •3\) Subjects receiving medications (e.g., steroids or antihistamines) would compromise the study.
  • •4\) Chronic illness which may influence the cutaneous state.
  • •5\) Subjects having any active dermatological skin diseases (e.g., psoriasis, atopic dermatitis, rosacea etc.), that might interfere with clinical assessments.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not yet recruiting
Phase 1
A Phase I clinical trial to study the effect of two drugs, Insulin Glargine manufactured by BioGenomics limited and Lantus® by comparing pharmacokinetic and pharmacodynamic properties, safety and tolerability in healthy male volunteers.
CTRI/2022/09/045313BioGenomics Ltd
Recruiting
Phase 1
Phase-I clinical trial of Stelis Insulin Glargine injection 100IU/mL in healthy adults
CTRI/2020/12/030079Stelis Biopharma Pvt Ltd
Active, not recruiting
Not Applicable
Study to determine the pH produced in the stomach and oesophagus after taking Gaviscon Double Action Liquid Vs Placebo.To pilot the use of a novel pH catheter for the measurement of oesophageal and intragastric pH comparing the onset and duration of antacid action of Gaviscon Double Action versus placebo.Therapeutic area: Body processes [G] - Digestive System and Oral Physiological Phenomena [G10]
EUCTR2011-004725-27-GBReckitt Benckiser Healthcare (UK) Ltd
Completed
Not Applicable
A single-center, randomized, double-blind, double-dummy, placebo- and active-controlled, 4-way cross-over study to assess next-day driving performance following single and multiple evening administrations of ACT-541468 in middle-aged and elderly subjects.
NL-OMON48154Idorsia Pharaceuticals Ltd.56
Completed
Not Applicable
A single-center, randomized, double-blind, two-period cross-over study to investigate the effect of a single intravenous dose of rifampicin on the pharmacokinetics of ACT-246475 in healthy subjects.
NL-OMON46064Idorsia Pharmaceuticals Ltd14